Heron Therapeutics (HRTX)

• Market cap: $335M
• 1 day: 3.42%
• 5 days: 9.01%
• 1 month: 10.00%
• 3 months: 39.88%
• 6 months: 34.44%
• Year to date: 51.25%
• 1 year: 4.31%
• 5 years: -83.03%
• 10 years: -77.59%
• Sector: Healthcare
• Industry: Biotechnology

About: Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Employees: 122

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

7,109% more call options, than puts

Call options by funds: $4.61M | Put options by funds: $64K

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

4.75% less ownership

Funds ownership: 80.32% [Q3] → 75.57% (-4.75%) [Q4]

6% less funds holding

Funds holding: 172 [Q3] → 161 (-11) [Q4]

16% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 50

24% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 34

27% less capital invested

Capital invested by funds: $242M [Q3] → $176M (-$66.6M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 65% upside
• Avg. target: $4 65% upside
• High target: $4 65% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Needham Serge Belanger 50% 1-year accuracy 62 / 125 met price target

65% upside $4

Buy Reiterated

11 Apr 2025